Biomarker-Based Blood Test Assesses Risk for Diabetic Kidney Disease Before Symptoms Appear

Diabetic kidney disease (DKD) is a serious health condition that often goes undetected until irreparable damage has been done to the kidneys and kidney function. One-in-three adults with diabetes will develop kidney disease. And, in 90% of cases, they won’t know they have it until it has advanced to the point where they need dialysis or a kidney transplant to survive, as it develops slowly and without symptoms. Now, the first and only scientifically-based screening technology provides an early read on the risk of developing kidney disease for people with diabetes, giving them and their doctors time to take preventative action and improve outcomes.

Journey Biosciences, Inc. (Lebanon, NH, USA) has launched NaviDKD, a biomarker-based blood test that proactively assesses the risk of kidney disease in people with diabetes years before clinical signs or symptoms appear. Along with its proprietary Compass reporting platform, NaviDKD provides actionable insights for preventing and managing kidney complications before they occur. NaviDKD is the first and only scientifically-proven predictive screening for DKD and provides healthcare providers with the insights needed to preserve their patients' kidney health, avoid complications, and improve outcomes.

By proactively assessing risk 10+ years in advance of clinical signs and symptoms, NaviDKD provides the opportunity to treat with therapeutics and technologies to change the outcome. By combining the simplicity of a blood test with the advanced science of predictive biomarkers, NaviDKD gives healthcare providers and their patients an early alert of their individual risk - giving a decade or more to make informed decisions that preserve their kidney health.

"For the one-in-three people with diabetes who will develop diabetic kidney disease, NaviDKD provides an opportunity to fundamentally change their ultimate health outcomes," said Adam Graybill, Chief Executive Officer of Journey Biosciences. "By identifying those at elevated or high risk of developing DKD before any symptoms or clinical indications, the conversation between doctor and patient can focus on taking proactive, preventative action instead of reacting to an unwanted diagnosis."

Related Links:
Journey Biosciences, Inc.

Visit expo >

Platinum Member

COVID-19 Rapid Test

OSOM COVID-19 Antigen Rapid Test

Magnetic Bead Separation Modules
MAG and HEATMAG

Complement 3 (C3) Test

GPP-100 C3 Kit

Gold Member

Systemic Autoimmune Testing Assay

BioPlex 2200 ANA Screen with MDSS